Drug Profile
Research programme: stem cell therapies - Gamida Cell
Alternative Names: GC 014; GC 015; Israel Stem Cell Therapy Consortium; Stem cell technologies research programme - Gamida CellLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ben Gurion University; Gamida-Cell; Hadassah Medical Organization; Hebrew University of Jerusalem; Technion - Israel Institute of Technology; Tel Aviv University; The Tel Aviv Sourasky Medical Center
- Developer Gamida-Cell; Weill Cornell Medical College
- Class Stem cell therapies
- Mechanism of Action Haemoglobin stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Beta-thalassaemia; Burns; Musculoskeletal disorders; Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Beta-thalassaemia in Israel
- 16 Jul 2016 No recent reports of development identified for preclinical development in Burns in Israel
- 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in Israel